Inflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior
NCT ID: NCT06047613
Last Updated: 2023-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2023-10-05
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that peripheral inflammation may alter the blood brain barrier, which normally acts as a filter to ensure proper neuronal functioning, in suicidal patients.
They propose to investigate peripheral inflammation, neurovascular permeability and miRNAs in suicidal behavior pathophysiology as biomarkers of suicidal behavior in depression
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* 50 Suicide attempters, i.e. currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempts, including the most recent);
* 50 Affective controls, i.e. currently depressed patients without any lifetime history of suicide attempt;
* 50 Healthy controls (age- and gender-matched to patients' groups) with no lifetime history of psychiatric disorders.
The protocol includes two visits for patients (suicide attempters and affective controls) and only one visit (inclusion) for healthy controls.
The first visit is the inclusion visit (Day 0-Day 8). Day 0 is the date of the last suicide attempt for the suicide attempters group and the date of signature of the consent for the affective control and healthy control groups. All the visit exams will be performed within 8 days after Day 0.
The second visit takes place one month +/- one week after inclusion. At each visit, a clinical assessment will be performed to characterise psychopathology and suicidal characteristics. Blood samples will be obtained in order to measure inflammatory markers. An MRI will be performed on order to study white matter microstructure and brain functional connectivity networks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Suicide attempters
Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent );
Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
Affective controls
Currently depressed patients without any lifetime history of suicide attempt
Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
Healthy controls
Participants with no lifetime history of psychiatric disorders
Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliated to a French National Social Security System
* Able to understand the nature, purpose and methodology of the study
* Able to give written informed consent
Suicide attempters:
* Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion)
* Subject with a recent history of proven suicide attempt (within the 8 days before inclusion)
* Subject with a history of maximum 2 previous lifetime proven SA
Affective controls:
* Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion),
* Subject without any lifetime history suicidal behavior (proven, interrupted or aborted)
Healthy controls:
\- Subject who have no current or past personal history of psychiatric disorders according to DSM5 criteria.
* History of psychotic disorders
* Diagnostic of illicit substance / alcohol use disorder within the last 6 months
* Current inflammation-related symptoms including fever and infectious or inflammatory disease
* Severe symptomatic or unstable medical condition (e.g., unstable endocrine or cardiovascular disease)
* Medical disorders affecting CNS function (e.g., history of severe head trauma, epilepsy, tumor)
* Current use of specific medications known to affect the immune system, such as corticosteroids, non-steroid anti-inflammatory drugs, aspirin and statins
* Contraindication to MRI or impossibility to assess, or doubt about a contraindication to the MRI: metallic artificial heart valve, pacemaker, cerebrovascular clips ferromagnetic materials, metallic foreign body that can be mobilized, in particular cerebral or intraocular, prosthesis ferromagnetic, impossibility of absolute immobility in supine position, claustrophobia.
* Vaccination in the last month
* Law protected or deprived of liberty subject
* Pregnant and breastfeeding women
* BMI \> 30 kg/m2
* Having reached 6000€ annual compensation for participating to clinical trials
* Being in exclusion period for another study
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jessica DALAUDIERE
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL22_0103
Identifier Type: -
Identifier Source: org_study_id